Top

Published in:

01-06-2016

Epithelioid Hemangioendothelioma: a Rare Primary Thyroid Tumor with Confirmation of WWTR1 and CAMTA1 Rearrangements

Authors: Akeesha A. Shah, N. Paul Ohori, Linwah Yip, Christopher Coyne, Cristina R. Antonescu, Raja R. Seethala

Published in: Endocrine Pathology | Issue 2/2016

Abstract

We report a rare case of epithelioid hemangioendothelioma as a primary thyroid tumor. To our knowledge, there are only two prior unequivocal cases of primary thyroid epithelioid hemangioendothelioma reported in the English literature. This is the first case in the thyroid with molecular confirmation.

Weiss SW, Enzinger FM. Epithelioid hemangioendothelioma: a vascular tumor often mistaken for a carcinoma. Cancer 1982;50:970–981.CrossRefPubMed

Dail DH, Liebow AA. Intravascular bronchioloalveolar tumor (abstr). Am J Pathol 1975;78:6a-7a.

Murali R, Zarka MA, Ocal IT, Tazelaar. Cytologic features of epithelioid hemangioendothelioma. Am J Clin Pathol 2011;136:739–746.CrossRefPubMed

Mentzel T, Beham A, Calonje E, Katenkamp D, Fletcher CDM. Epithelioid hemangioendothelioma of skin and soft tissues: clinicopathologic and immunohistochemical study of 30 cases. Am J Surg Pathol 1997;21(4):363–374.CrossRefPubMed

Deyrup AT, Tighiouart M, Montag AG, Weiss SW. Epithelioid Hemangioendothelioma of Soft Tissue: A Proposal for Risk Stratification Based on 49 Cases. Am J Surg Pathol 2008;32:924–927.CrossRefPubMed

Antonescu C. Malignant vascular tumors-an update. Mod Pathol 2014;27:S30-S38.CrossRefPubMed

Mendlick MR, Nelson M, Pickering D, Johansson SL, Seemayer TA, Neff JR, Vergara G, Rosenthal H, Bridge JA. Translocation t(1;3)(p36.3;q25) is a nonrandom aberration in epithelioid hemangioendothelioma. Am J Surg Pathol. 2001 May;25(5):684–7.

Tanas MR, Sboner A, Oliveira AM, Erickson-Johnson MR, Hespelt J, Hanwright PJ, Flanagan J, Luo Y, Fenwick K, Natrajan R, Mitsopoulos C, Zvelebil M, Hoch BL, Weiss SW, Debiec-Rychter M, Sciot R, West RB, Lazar AJ, Ashworth A, Reis-Filho JS, Lord CJ, Gerstein MB, Rubin MA, Rubin BP. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med. 2011 Aug 31;3(98):98ra82.

Errani C, Zhang L, Sung YS, Hajdu M, Singer S, Maki RG, Healey JH, Antonescu CR. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer. 2011 Aug;50(8):644–53.

10.

Antonescu CR, Le Loarer F, Mosquera JM, Sboner A, Zhang L, Chen CL, Chen HW, Pathan N, Krausz T, Dickson BC, Weinreb I, Rubin MA, Hameed M, Fletcher CD. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer. 2013 Aug;52(8):775–84.

11.

Patel NR, Salim AA, Sayeed H, Sarabia SF, Hollingsworth F, Warren M, Jakacky J, Tanas M, Oliveira AM, Rubin BP, Lazar AJ, López-Terrada D, Wang WL . Molecular characterization of epithelioid haemangioendotheliomas identifies novel WWTR1-CAMTA1 fusion variants. Histopathology. 2015 Nov;67(5):699–708.

12.

Baloch ZW, LiVolsi VA. Unusual tumors of the thyroid gland. Endocrinol Metab Clin North Am. 2008 Jun;37(2):297–310

13.

Kaur A, Didolkar MS, Thomas A. Angiosarcoma of the thyroid: a case report with review of the literature. Endocr Pathol. 2013 Sep;24(3):156–61.

14.

Zhang X, el-Sahrigy D, Elhosseiny A, Melamed MR. Simultaneous cytomegalovirus infection and Kaposi’s sarcoma of the thyroid diagnosed by fine-needle aspiration in an AIDS patient. A case report and first cytologic description of the two entities occurring together. Acta Cytol 47: 645–648, 2003.CrossRefPubMed

15.

Poniecka A, Ghorab Z, Arnold D, Khaled A, Ganjei-Azar P. Kaposi’s sarcoma of the thyroid gland in an HIV-negative woman: a case report. Acta Cytol. 2007 May-Jun;51(3):421–3.

16.

Siddiqui MT, Evans HL, Ro JY, Ayala AG. Epithelioid haemangioendothelioma of the thyroid gland: a case report and review of literature. Histopathology. 1998 May;32(5):473–6.

17.

Hassan I, Barth P, Celik I, Hoffmann S, Langer P, Ramaswamy A, Wagner HJ, Rothmund M, Zielke A. An authentic malignant epithelioid hemangioendothelioma of the thyroid: a case report and review of the literature. Thyroid. 2005 Dec;15(12):1377–81.

18.

Surov A, Gottschling S, Wienke A, Meyer HJ, Spielmann RP, Dralle H. Primary Thyroid Sarcoma: A Systematic Review. Anticancer Res. 2015 Oct;35(10):5185–91.

19.

Tötsch M, Dobler G, Feichtinger H, Sandbichler P, Ladurner D, Schmid KW. Malignant hemangioendothelioma of the thyroid. Its immunohistochemical discrimination from undifferentiated thyroid carcinoma. Am J Surg Pathol. 1990 Jan;14(1):69–74.

20.

Requena L, Kutzner H. Hemangioendothelioma. Semin Diagn Pathol. 2013;30:29–44.CrossRefPubMed

21.

Weiss SW, Ishak KG, Dail DH, Sweet DE, Enzinger FM. Epithelioid hemangioendothelioma and related lesions. Semin Diagn Pathol. 1986;3:259–287.PubMed

22.

Rosai J, DeLellis RA, Carcangiu ML, Frable WJ, Tallini G. AFIP Atlas of Tumor Pathology: Tumors of the Thyroid and Parathyroid Glands. Silver Spring: ARP Press. 2014. Print.

23.

Gray MH, Rosenberg AE, Dickersin GR, Bhan AK. Cytokeratin expression in epithelioid vascular neoplasms. Hum Pathol. 1990 Feb;21(2):212–7.

24.

Doyle LA, Fletcher CD, Hornick JL. Nuclear Expression of CAMTA1 Distinguishes Epithelioid Hemangioendothelioma From Histologic Mimics. Am J Surg Pathol. 2015 Sep 24. [Epub ahead of print].

Title: Epithelioid Hemangioendothelioma: a Rare Primary Thyroid Tumor with Confirmation of WWTR1 and CAMTA1 Rearrangements
Authors: Akeesha A. Shah
N. Paul Ohori
Linwah Yip
Christopher Coyne
Cristina R. Antonescu
Raja R. Seethala
Publication date: 01-06-2016
Publisher: Springer US
Published in: Endocrine Pathology / Issue 2/2016
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI: https://doi.org/10.1007/s12022-016-9428-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

Establishment and Characterization of a Human Neuroendocrine Tumor Xenograft

Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF V600E Harboring Pediatric Papillary Thyroid Carcinomas

A Novel Mutation in a Patient with Hyperparathyroidism–Jaw Tumour Syndrome

An Unusual Solitary Thyroid Nodule with Bloody Follicles: Metastatic Renal Cell Carcinoma Within an Infiltrative Follicular Variant Papillary Carcinoma

The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors

Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials